Oral treatment for multiple sclerosis
Authors:
- 1 November 2011
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 10 (11) , 1026-1034
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]Neurology, 2010
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesThe Lancet Neurology, 2010
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Interrupted therapyNeurology, 2003
- Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialThe Lancet, 2002
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995